Edwards sapien m3 receives ce mark, becoming world's first transfemoral transcatheter mitral valve replacement system

Irvine, calif.--(business wire)--edwards lifesciences corporation (nyse: ew) today announced the company's sapien m3 mitral valve replacement system received ce mark for the transcatheter treatment of patients with symptomatic (moderate-to-severe or severe) mitral regurgitation (mr) who are deemed unsuitable for surgery or transcatheter edge-to-edge (teer) therapy. leveraging the company's sapien technology, the sapien m3 system is the world's first approved transcatheter valve replacement ther.
EW Ratings Summary
EW Quant Ranking